FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from clinical trials for educational reference.

Tirzepatide vial

Dual GIP/GLP-1 Agonist

Tirzepatide

  • LY3298176
  • GIP/GLP-1 dual receptor co-agonist

A 39-amino acid dual GIP and GLP-1 receptor agonist with a fatty-acid modification for once-weekly action. Studied extensively for glycemic control and weight management.

Dosage
Quantity
$249.00
View CoA
or check out in one tap
Ships in 24-48h
Free shipment protection
Overnight available
We accept Apple Pay Visa
Free shipping on orders over $150
Damage protection
Secure checkout 256-bit SSL

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

Latest

99.0%

Purity

Variant Tirzepatide 20MG
Lot # SAMPLE-PENDING
Labeled 20.00 mg
Actual —
Tested Pending

Frequently Researched Together

Commonly studied alongside other weight & metabolism compounds

RT-20

RT-20

Weight & Metabolism

From $249

Compound Information

Technical specifications

Molecular Profile

What Is Tirzepatide?

Type Dual GIP/GLP-1 receptor agonist (39 aa)
CAS Number 2023788-19-2
Molecular Weight 4813.45 g/mol
Amino Acids 39 (contains Aib)
Formula C225H348N48O68
PubChem Database
Storage Requirements

Stability Information

  • Lyophilized — long-term stable
  • Protect from light
  • Reconstitute with bacteriostatic water
Lyophilized (powder) −20°C · stable 24+ months
Reconstituted 2–8°C · use within 30 days
Handling Avoid repeated freeze-thaw

Sources & References

Peer-reviewed research

Mol Metab

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept

2018 · DOI: 10.1016/j.molmet.2018.09.009

Coskun T, Sloop KW, Loghin C et al.

View Source

Lancet

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

2018

Frías JP et al.

View Source

JCI Insight

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

2020 · DOI: 10.1172/jci.insight.140532

Willard FS et al.

View Source

Lancet

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

2021 · DOI: 10.1016/S0140-6736(21)01324-6

Rosenstock J, Wysham C, Frías JP et al.

View Source

N Engl J Med

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)

2021 · DOI: 10.1056/NEJMoa2107519

Frías JP, Davies MJ, Rosenstock J et al.

View Source

Lancet

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

2021 · DOI: 10.1016/S0140-6736(21)02188-7

Del Prato S, Kahn SE, Pavo I et al.

View Source

N Engl J Med

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

2022 · DOI: 10.1056/NEJMoa2206038

Jastreboff AM, Aronne LJ, Ahmad NN et al.

View Source

Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

All the research peptides you need, with the peace of mind and research community at your fingertips.

Shop Now

Research updates from SFSC

Subscribe for catalog updates, new research compounds, and quality documentation news

For researchers and labs. No spam, unsubscribe anytime.

Subscribed — coming soon!

Scroll to Top